MPLT Chief Scientific Officer Lillie Sells $93K of Stock

Inside James Woodruff Lillie's MPLT Trade

MapLight Therapeutics, Inc. Chief Scientific Officer James Woodruff Lillie sold 11,513 shares of the company on October 15, 2026. The shares changed hands at an average price of $8.08, bringing the total value of the transaction to $93,025.04. The insider filed the required Form 4 paperwork with the Securities and Exchange Commission to detail the sale.

Other Institutional Activity in MapLight Therapeutics, Inc.

Large investors hold significant stakes in the biotechnology company. Novo Holdings A/S held 3,686,622 shares valued at about $28,386,988 in its report for the period ending June 30, 2026. FCPM III Services B.V. maintained 3,226,400 shares worth roughly $24,843,279. Nan Fung Group Holdings Limited owned 971,253 shares valued at about $7,478,647. 5AM Venture Management, LLC held 950,011 shares worth roughly $7,315,084, while Sanofi kept 912,041 shares valued at about $7,022,715.

Insider Buying and Selling at MapLight Therapeutics, Inc.

Insiders have been active in the stock over recent months. Director Troy M Cox bought 15,620 shares on July 28, 2026, at $12.31 apiece for $192,282. Beneficial owner Inc. Catalyst4 picked up 1,209,225 shares on July 30, 2026, worth $15,314,794. James Woodruff Lillie previously sold 22,082 shares on August 3, 2026, at $12.54 per share for $276,908. Later in the summer, Inc. Catalyst4 bought another 4,400,000 shares on August 14, 2026, at $11.38 each for $50,072,000.

Analysts Set New Price Targets

On July 28, 2026, Canaccord Genuity maintained its Buy rating on the stock while adjusting its price target from $43.00 to $24.00. On the same day, Morgan Stanley downgraded the shares to Equal-Weight and lowered its target from $34.00 to $21.00. UBS followed on August 10, 2026, by downgrading the stock to Neutral and reducing its target from $52.00 to $13.00. Needham maintained a Buy rating on August 31, 2026, while moving its target from $45.00 to $43.00. Guggenheim initiated coverage with a Neutral rating on October 6, 2026. The firm carries a consensus strong buy rating with a mean target price of $26.54 across 13 analyst opinions.

About MapLight Therapeutics, Inc.

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for patients suffering from debilitating central nervous system disorders. Headquartered in Redwood City, California, the organization advances targeted therapies using proprietary discovery platforms.

Bottom Line

Investors will look toward the company's next earnings report scheduled for November 12, 2026, for updates on its clinical pipeline. Regular SEC filings will continue to track executive and institutional portfolio adjustments.